AI in IVD market seen reaching $7.01 billion by 2030

The Business Research Company projects the artificial intelligence in in vitro diagnostics market will grow from $3.6 billion in 2026 to $7.01 billion by 2030, driven by personalized medicine, cloud diagnostics and AI-powered testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - AI is changing how lab tests are interpreted, with potential to speed diagnosis and support more personalized treatment decisions. - The market outlook points to sustained demand for AI tools in diagnostics as healthcare systems push for faster, more precise and lower-cost testing. - The forecast suggests the category could become a bigger part of lab workflows, especially as personalized medicine and genomic testing expand.

What happened: - The Business Research Company released its 2026 report on the artificial intelligence in in vitro diagnostics market, covering market size, trends and a forecast through 2035. - The report says the market will rise from $3.04 billion in 2025 to $3.6 billion in 2026, a CAGR of 18.4%. - The report projects the market will reach $7.01 billion by 2030, with a forecast CAGR of 18.1%. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - AI in IVD uses algorithms to analyze data from lab tests on samples such as blood, tissue and urine. - The technology is designed to produce faster and more precise interpretation of diagnostic results. - The report links near-term growth to cloud-based diagnostic platforms, AI and genomic technology integration, AI-powered point-of-care testing, investment in personalized medicine and demand for quick, cost-efficient diagnostics. - The report says emerging trends include AI-driven lab automation, predictive diagnostics, data-centric test interpretation, cloud diagnostics and personalized patient profiling. - The report says historical growth was supported by demand for accurate diagnostic tools, better laboratory infrastructure, rising chronic disease prevalence, broader adoption of digital diagnostics and biomarker research. - The report says personalized medicine is a major driver because it tailors prevention, diagnosis and therapy to a person’s genetic makeup, lifestyle and environment. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six the year before. - That same set of approvals included seven cancer drugs and three treatments for other conditions. - The report’s regional coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also highlights new analytical features in its 2026 market reports, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - A free sample report and the full market report are available online.

Between the lines: - The growth rate signals that AI in diagnostics is moving from a niche technology into a broader healthcare infrastructure play. - The emphasis on personalized medicine and genomic data suggests future demand will center on tools that can turn complex biological data into actionable clinical guidance. - The regional split hints that mature healthcare markets are leading adoption now, while faster growth may come from expanding digital health investment in Asia-Pacific.

What's next: - The report expects AI-powered lab automation, cloud diagnostics and predictive testing to shape the next phase of the market. - Continued investment in personalized medicine and point-of-care diagnostics is likely to support adoption through 2030 and beyond. - The Business Research Company says its report tracks the market through 2035, giving buyers and operators a longer-range view of the category’s trajectory.

The bottom line: - AI in in vitro diagnostics is forecast to more than double by 2030, with personalized medicine and cloud-based testing driving the next leg of growth.